All Clinical Trials

Note: The LRG uses ClinicalTrials.gov and other sources to compile the LRG Clinical Trials database. Click on the name (title) to see the trial details in the LRG database. Click on the NCT link (below) to see the trial details in ClinicalTrials.gov.

293 trials found   

Drug

NCT#

Imatinib A Prospective, Multicenter Study on Best Clinical Use of Imatinib in the Advanced Gastrointestinal Stromal Tumors
2
None Kinase Genotyping of Gastro Intestinal Stomach Tumors (GISTs) From Patients Enrolled in Pfizer A6181112 Phase IIIb Trial
Avapritinib (CS3007) A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor
1/2
Imatinib + BGJ398 BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
1/2
Imatinib + PDR001 PDR001 Plus Imatinib for Metastatic or Unresectable GIST
1/2
Imatinib + Selinexor Selinexor in Combination With Imatinib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors. (SeliGIST)
1/2
Imatinib Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST) (Japan CSTI571BJP07)
4
Imatinib + Sunitinib + Regorafenib Treatment Response Evaluation in Gastrointestinal Stromal Tumor (GIST) Patients
4
Sunitinib Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor (GIST)
4
Detection of CF-DNA in Patients With Gastrointestinal Stromal Tumors (GIST)
3
Avapritinib or Regorafenib (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
3
Crenolanib (CP-868,596) Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST
3
Imatinib Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor (S0033)
3
Imatinib Imatinib Mesylate (Gleevec; STI571) in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed by Surgery (ACOSOG-Z9001)
3
Imatinib Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor (EORTC-62024)
3
Imatinib Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST) (SSGXVIII/AIO)
3
Imatinib Open-Label Trial of Glivec With Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors
3
Imatinib Prospective Multicentric Randomized Study of GlivecĀ® in Advanced Gastrointestinal Stromal Tumors Expressing c-Kit: Interruption After 5 Years vs Maintenance
3
Imatinib Imatinib Mesylate in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumor (EORTC-62005)
3
Imatinib Imatinib Mesylate With or Without Surgery in Treating Patients With Metastatic Gastrointestinal Stromal Tumor That is Responding to Imatinib Mesylate
3
Imatinib Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients
3
Imatinib Rechallenge of Imatinib in GIST Having no Effective Treatment (RIGHT)
3
Imatinib Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (ImadGist)
3
Imatinib Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST
3
Imatinib + Bevacizumab Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
3
IPI-504 Study of IPI-504 in GIST patients following failure of at least imatinib and sunitinib
3
L-carnitine L-carnitine vs Placebo for the Treatment of Muscle Cramps After Imatinib in Gastrointestinal Stromal Tumors
3
Masitinib or Sunitinib Masitinib 2nd Line versus Sunitinib in Advanced GIST
3
Masitinib, (AB1010) A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour in First Line Medical Treatment
3
Nilotinib Efficacy and Safety of AMN107 Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib (ENEST)
3
Nilotinib Efficacy and Safety of AMN107 Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib - Extension
3
Nilotinib Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib
3
Nilotinib or Imatinib Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg (LANGIST)
3
Nilotinib or Imatinib Phase III, Open-Label Study of Nilotinib Versus Imatinib in GIST Patients (ENESTg1)
3
QINLOCK Ripretinib DCC-2618 Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies (invictus)
3
QINLOCK Ripretinib DCC-2618 SUTENT Sunitinib A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib (intrigue)
3
Regorafenib (BAY 73-4506) Study of Regorafenib as a 3rd-line or Greater Treatment for Gastrointestinal Stromal Tumors (GIST) (GRID)
3
Regorafenib (BAY 73-4506) Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy
3
Sunitinib A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumors (Gist)
3
Sunitinib SU011248 in Treating Patients With Malignant Gastrointestinal Stromal Tumor
3

293 sites found